UNSPSC 51283000: Lincosamides

This classification denotes antibiotics belonging to a family of lincomycin-related glycosides that contain a pyrrolidine ring linked via an amide-bond to a pyranose moiety, hence the names LINCOS-AMIDE, LINCOSAMIDE, and LINCOSAMIDES. Individual members of this family are defined by the arrangement of specific constituent groups on the lyncomycin molecule.

UNSPSC 51283000 Lincosamides is a Class code that encompasses pharmaceutical products and related medical supplies procured by state and local health agencies, but recent state and local opportunities tagged under this code show substantial mismatch with the category's nominal scope. The code's title references a specific class of antibiotics (lincosamide compounds such as clindamycin), yet recent solicitations cover naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and medical first-aid supplies for emergency response — a much broader range of health-related commodities than the antibiotic family alone. State and local issuing bodies using this code include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), municipal purchasing departments supporting public safety (City of Tampa Fire Department), and cooperative purchasing alliances serving multi-state jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance for Oregon and Minnesota participants). The purchasing pattern reflects fragmented sourcing across health agencies rather than concentrated procurement.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative solicitations include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida (response deadline July 26, 2023); the City of Tampa's IFB for 169 line items of medical and first-aid supplies for the Fire Department Rescue Division, estimated at $700,000, with a small local business enterprise set-aside and 5 percent bid discount (response deadline March 13, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products across state and local facilities, with proposals due March 26, 2026 and products required available by May 15, 2026. The Texas HHS Commission also posted an RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026), signaling forward exploration of pharmacy benefit sourcing models. The code shows recent activity but lacks coherent alignment with lincosamide-specific procurement; vendors should verify actual commodity scope in each solicitation's scope of work rather than relying on the code name alone.